Dr. George J. Chang Article Highlights While curative-intent treatment of patients with oligometastatic colorectal cancer is already considered standard practice, the role of local ablative therapies to render patients disease free is less clear in patients with multisite, limited disease who would not be traditionally considered candidates for curative resection. Advances…
PURPOSETo evaluate the safety and efficacy of zipalertinib, an irreversible epidermal growth factor receptor (EGFR) inhibitor, in pretreated patients with non–small cell lung cancer (NSCLC)…
PURPOSEAzacitidine and venetoclax is a standard frontline treatment regimen for newly diagnosed older adults with AML; however, long-term outcomes remain poor. Revumenib is an oral…
Purpose:To report results of the multicenter, open-label IRAKLIA trial (NCT05405166) of isatuximab subcutaneous (SC) versus intravenous (IV), plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma…
PURPOSEPirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III…
PurposeAdjuvant treatment with immune checkpoint inhibition (PD1) and targeted therapy (TT) with BRAF+MEK inhibitors significantly improved recurrence-free survival (RFS) of stage III melanoma patients. We…
BackgroundWe report Phase 1 trial results for pasritamig, a first-in-class, T-cell engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of prostate…
PURPOSEContinuous use of antiangiogenic agents has demonstrated survival benefits in various cancers. This trial aimed to compare the efficacy and safety of ramucirumab plus irinotecan…
PURPOSESurviving cancer has significant financial implications for adolescents and young adults (AYAs). It is unclear how cancer affects AYA income over time compared with the…
PURPOSE Despite limited RCTs, neoadjuvant chemotherapy (NAC) shows promise for resectable pancreatic adenocarcinoma (rPAC). Few prospective results are available on completing the full therapeutic sequence…
Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment options with relatively low efficacy. Lifileucel, a one-time autologous tumor-infiltrating lymphocyte cell…
